Amneal Pharmaceuticals, Inc. (AMRX) Cash Flow Statement

The 2026 quarters show operating cash flow of -$28.7M and -$19.3M against net income of $62.3M and $57.7M, an accrual gap that is hard to reconcile with a stable operating base. Working capital outflows of roughly $190M per quarter in the first two quarters of 2026 appear to be the primary driver, which warrants investigation into receivables, inventory, and gross-to-net timing. Investors should monitor whether the strong third-quarter rebound reflects genuine collection normalization or a timing shift.

Free cash flow margins ranged from -8.1% to 17.2% across the ten reported quarters, a spread too wide to treat any single period as representative. The trend appears to be driven more by working capital timing than by underlying profitability, given that depreciation and amortization stayed steady near $43M to $66M per quarter. Until cash conversion stabilizes across several consecutive quarters, the reported FCF level should be treated with caution.

Most quarters show capex in the low single digits as a share of revenue, consistent with a manufacturing base that requires ongoing maintenance investment. The 2026Q2 spike appears unusually large relative to surrounding quarters and may reflect facility or biosimilar capacity investment, though the filings do not allow a clean split between maintenance and growth spend. Depreciation near $50M per quarter suggests capex has not been fully replacing asset consumption in several periods.

Large recurring working capital outflows in early 2026 point to a build in receivables or inventory, which is consistent with gross-to-net adjustment timing and generic price erosion. The reversal in 2026Q3 to a modest outflow of $29.2M suggests partial normalization, but one quarter is insufficient to confirm a structural improvement. Investors should monitor days sales outstanding and inventory levels in upcoming filings.

The $420.6M acquisition outflow in the latest quarter is large relative to quarterly free cash flow of $60.7M, implying it was funded substantially by balance sheet resources or new borrowing. The absence of shareholder returns is consistent with a company prioritizing deleveraging given debt-to-equity of 458.91%. Whether this acquisition generates returns sufficient to justify the spend cannot be assessed from the supplied data alone.